JAK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL30925	0.64	20/20
SCHEMBL20626	0.59	20/20
SCHEMBL21039	0.53	19/20
SCHEMBL30932	0.50	19/20
SCHEMBL47247	0.75	17/20
SCHEMBL19153	0.58	17/20
SCHEMBL30966	0.57	17/20
SCHEMBL19111	0.56	17/20
SCHEMBL21968	0.54	17/20
SCHEMBL19675	0.53	17/20
SCHEMBL20311	0.51	17/20
SCHEMBL20765	0.63	16/20
SCHEMBL20543	0.60	16/20
SCHEMBL24181	0.56	16/20
SCHEMBL24481	0.54	16/20
SCHEMBL20007	0.53	16/20
SCHEMBL20773	0.53	16/20
SCHEMBL20913	0.51	16/20
SCHEMBL21661	0.51	16/20
SCHEMBL25160	0.51	16/20

Clinical trials — most relevant to JAK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	PHASE3	ACTIVE_NOT_RECRUITING
A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis	PHASE3	UNKNOWN
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.	PHASE2	COMPLETED
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF	PHASE1/PHASE2	COMPLETED
Ruxolitinib in Thrombocythemia and Polycythemia Vera	PHASE2	RECRUITING
Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia	PHASE2	RECRUITING
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET	PHASE2	ACTIVE_NOT_RECRUITING
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML	PHASE2	ACTIVE_NOT_RECRUITING
JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis	PHASE2	COMPLETED
Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata	PHASE2	COMPLETED
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders	PHASE2	RECRUITING
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)	PHASE2	COMPLETED
Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis	PHASE2	NOT_YET_RECRUITING
A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia	PHASE2	UNKNOWN
Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis	PHASE1	NOT_YET_RECRUITING
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients	PHASE1	RECRUITING
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia	PHASE1	COMPLETED
Itacitinib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions	PHASE1	COMPLETED
Ruxolitinib for Cancer Cachexia	EARLY_PHASE1	ACTIVE_NOT_RECRUITING
Cutaneous JAK in Vitiligo and Acne Vulgaris.	nan	UNKNOWN
Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo	nan	UNKNOWN
Molecular Disease Profile of Hematological Malignancies	nan	UNKNOWN
CircularRNA-microRNA-mRNA Regulatory Axis in IVF	nan	NOT_YET_RECRUITING
Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts	nan	COMPLETED
PCM1-JAK2 in Therapy Related Neoplasms	nan	UNKNOWN
Exploiting Leading Edge 7T MRI Brain Imaging to Decipher Olumiant's Mode of Analgesic Action in Rheumatoid Arthritis	nan	COMPLETED
Risk Factors and Predictors of Thrombosis in Myeloprolferative Neoplasms	nan	UNKNOWN
Ruxolitinib in Patients With Myelofibrosis	nan	UNKNOWN
Role of Mesenchymal Stromal Cell Derived Extracellular Vesicles of Primary Myelofibrosis Patients on CD34+ Cells	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a JAK2 binder may also engage these)

Protein	Name	Similarity
Q62689	—	1.000	Q62689 →
Q62120	—	1.000	Q62120 →
Q75R65	—	1.000	Q75R65 →
Q5RB23	—	1.000	Q5RB23 →
O12990	—	1.000	O12990 →
P52332	—	1.000	P52332 →
O19064	—	1.000	O19064 →
Q24592	—	0.998	Q24592 →
Q09178	—	0.997	Q09178 →
G5EFD2	—	0.994	G5EFD2 →
JAK1	Tyrosine-protein kinase JAK1	0.993	landscape →
P43481	—	0.992	P43481 →
P26619	—	0.991	P26619 →
Q6GM53	—	0.991	Q6GM53 →
P70600	—	0.991	P70600 →
Q22070	—	0.990	Q22070 →
Q2HWD6	—	0.990	Q2HWD6 →
Q76II0	—	0.990	Q76II0 →
Q9I8N6	—	0.990	Q9I8N6 →
Q9VEZ5	—	0.990	Q9VEZ5 →
Q6GM71	—	0.990	Q6GM71 →
Q8AXC7	—	0.990	Q8AXC7 →
Q28317	—	0.990	Q28317 →
Q8I4N4	—	0.990	Q8I4N4 →
G5EGT9	—	0.990	G5EGT9 →
Q9VV73	—	0.990	Q9VV73 →
Q28889	—	0.990	Q28889 →
Q09639	—	0.989	Q09639 →
F1REV3	—	0.989	F1REV3 →
Q08156	—	0.989	Q08156 →